Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wave Life Sciences ( (WVE) ) has provided an announcement.
On February 2, 2026, Wave Life Sciences announced that it has regained full rights to WVE-006, its first-in-class GalNAc-conjugated RNA editing candidate for alpha-1 antitrypsin deficiency (AATD), from partner GSK, enabling the company to accelerate its registrational strategy for this rare disease asset. Wave said it plans to seek U.S. Food and Drug Administration feedback by mid-2026 on a potential accelerated approval pathway for WVE-006, which is designed to address both lung and liver manifestations of AATD and has shown a favorable safety profile to date, with additional data from the ongoing RestorAATion-2 trial’s 400 mg multidose cohort expected in the first quarter of 2026 and from 600 mg cohorts later in the year. The company’s broader collaboration with GSK remains in place and expanded in January 2026 with the selection of a fourth oligonucleotide program, under a deal that could yield up to $2.8 billion in milestones and royalties, while Wave reiterated that its current cash resources are expected to fund operations into the third quarter of 2028, underscoring a solid financial runway to advance its RNA medicines pipeline.
The most recent analyst rating on (WVE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.
Spark’s Take on WVE Stock
According to Spark, TipRanks’ AI Analyst, WVE is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative cash flows) despite revenue growth. Offsetting this, the latest earnings call was constructive with meaningful clinical progress and runway visibility, while technicals are mixed (longer-term strength but near-term softness). Valuation remains difficult to assess due to negative earnings and no dividend data.
To see Spark’s full report on WVE stock, click here.
More about Wave Life Sciences
Wave Life Sciences Ltd., based in Cambridge, Mass., is a clinical-stage biotechnology company focused on developing RNA-based medicines using its PRISM platform, which spans RNA interference, editing, splicing and antisense silencing modalities. The company’s diversified pipeline targets both rare and common disorders, including obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and Huntington’s disease, reflecting a strategy to leverage RNA therapeutics across multiple high-need indications.
Average Trading Volume: 6,891,943
Technical Sentiment Signal: Buy
Current Market Cap: $2.37B
For a thorough assessment of WVE stock, go to TipRanks’ Stock Analysis page.